Core Research

Melanotan II vs PT-141: Receptor-Binding Selectivity

Melanotan II (MT-II) and PT-141/bremelanotide are closely related cyclic melanocortin analogues, but they are not chemically identical. Their overlap in melanocortin receptor systems is a reason to compare exact structural and assay evidence—not to treat them as interchangeable products or to rank them for human outcomes.

Research Use Only: This page addresses molecular identity, receptor evidence and laboratory documentation. It does not provide human or veterinary dosing, administration or therapeutic recommendations.

What is the molecular difference between MT-II and PT-141?

Reference chemical structures describe MT-II as a cyclised α-MSH-derived heptapeptide with a C-terminal amide, while bremelanotide/PT-141 is a closely related cyclic heptapeptide with a free carboxyl terminus. Both contain a related constrained melanocortin scaffold, but this terminal-form distinction changes their molecular identity and expected analytical mass.

The PubChem MT-II record and PubChem bremelanotide record establish these reference chemical entities. Their canonical structures are not certificates for the material inside a Core Research container. The actual supplied molecular form, any counter-ion and the batch’s analytical findings belong to the applicable supplier documentation.

Comparison MT-II PT-141 / bremelanotide
General scaffold Cyclic melanocortin/α-MSH-related heptapeptide Closely related cyclic melanocortin heptapeptide
Reference terminal form C-terminal amide C-terminal free acid
Research family Broad melanocortin receptor pharmacology Melanocortin receptor pharmacology, with its own profile
What cannot be assumed That PT-141 shares the same molecular mass or all receptor effects That MT-II and its finished formats are equivalent to bremelanotide
Core Research catalogue page MT-II 10mg PT-141 10mg

Which receptor subtypes are relevant?

Melanocortin-receptor pharmacology commonly involves MC1R, MC3R, MC4R and MC5R, among other receptors depending on the assay question. Receptor binding and functional activation are distinct measurements. Neither molecule should be described as uniquely selective for one receptor subtype without a named experimental system and suitable original data.

The scientific literature includes receptor panels in transfected cells and structure–activity studies of modified melanocortin ligands. A review of melanocortin ligands and receptor assay measurements illustrates that receptor subtype and analogue identity can materially change potency estimates. Its tables summarise different original studies, not a single head-to-head comparison of the exact Core Research products.

A 1997 original receptor-ligand study found that changing the melanocortin peptide message sequence could alter the profile across human receptor subtypes. This supports a cautious structure–activity interpretation. It is not direct evidence that the two stocked commercial materials have equal or unequal potency in any specified assay.

Why binding cannot be converted into a broad outcome ranking

A ligand can displace a tracer in a receptor-binding assay; another experiment may measure cAMP or other downstream signalling; a third may examine a cell or whole-animal readout. Those endpoints are not interchangeable.

For example, a result in a melanocortin receptor-expression system cannot establish a universal effect in skin cells, neuroendocrine tissue or a particular human clinical setting. Receptor expression, signalling background, species and assay endpoint may differ. The same applies when comparing papers about MT-II and studies describing bremelanotide in a distinct medicinal formulation.

Study characteristic What should be checked Why it matters
Chemical form Exact peptide sequence, cyclisation and terminal chemistry An amide/free-acid difference changes identity
Receptor subtype MC1R, MC3R, MC4R or MC5R, with named species Potency may differ by subtype
Assay type Binding, receptor signalling, cellular phenotype or organism-level response These are different evidence layers
Comparator Identical conditions for both ligands or separate publications? Separate studies do not constitute a head-to-head comparison
Formulation Purified ligand, experimental carrier or finished medicinal formulation Delivery vehicle and standards can differ
Reported limitations Negative findings, tested range, assay sensitivity and uncertainty Prevents overclaiming selectivity or clinical relevance

What does the existence of a regulated bremelanotide medicine mean here?

A medicinal product containing bremelanotide has regulatory status in certain jurisdictions, but that status applies to the specific authorised formulation and manufacturing controls, not to a separate RUO reagent sold under a similar chemical name. Do not import a medicine’s assessed quality, sterility, indications or human-use instructions into the Core Research catalogue entry.

This page is not a clinical comparison and deliberately does not restate personal-use indications or protocols. The appropriate value of the medicinal example is only to clarify that shared substance terminology does not imply equal finished-product status.

Interpreting a Core Research batch report

For either material, the laboratory should resolve the declared exact cyclic sequence, C-terminal form, counter-ion/salt information if stated and theoretical versus observed mass. HPLC can support a chromatographic profile under the tested method, but it does not alone demonstrate every attribute of identity, net content or sterility. A mass assignment supports a chemical-identity question but cannot guarantee formulation equivalence.

Use Batch Documentation and the CoA-reading guide. The melanocortin research matrix locates these entities relative to MT-I, while the MT-I versus MT-II comparison owns the linear-versus-cyclic question.

Research-use conclusion

The clearest defensible distinction is structural: MT-II and bremelanotide have related melanocortin scaffolds with different terminal chemical forms. Receptor findings must be tied to the exact molecule and assay. Neither molecular similarity nor literature on a finished medicine establishes the characteristics, effects or suitability of a Core Research RUO lot.

Selected sources

  1. U.S. National Library of Medicine. Melanotan II — PubChem CID 92432. Compound record. Reference sequence and molecular formula; not a supplier CoA.
  2. U.S. National Library of Medicine. Bremelanotide — PubChem CID 9941379. Compound record. Reference chemical identity.
  3. Discovery of prototype peptidomimetic agonists at the human melanocortin receptors MC1R and MC4R. Journal of Medicinal Chemistry, 1997. DOI: 10.1021/jm960840h. Structure–activity work with specified model ligands.
  4. Bench-Top to Clinical Therapies: A Review of Melanocortin Ligands from 1954 to 2016. 2017. PubMed Central. Secondary review; not direct product testing.